Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease

Emiko Sato, Takefumi Mori, Eikan Mishima, Arisa Suzuki, Sanae Sugawara, Naho Kurasawa, Daisuke Saigusa, Daisuke Miura, Tomomi Morikawa-Ichinose, Ritsumi Saito, Ikuko Oba-Yabana, Yuji Oe, Kiyomi Kisu, Eri Naganuma, Kenji Koizumi, Takayuki Mokudai, Yoshimi Niwano, Tai Kudo, Chitose Suzuki, Nobuyuki TakahashiHiroshi Sato, Takaaki Abe, Toshimitsu Niwa, Sadayoshi Ito

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    Sarcopenia is associated with increased morbidity and mortality in chronic kidney disease (CKD). Pathogenic mechanism of skeletal muscle loss in CKD, which is defined as uremic sarcopenia, remains unclear. We found that causative pathological mechanism of uremic sarcopenia is metabolic alterations by uremic toxin indoxyl sulfate. Imaging mass spectrometry revealed indoxyl sulfate accumulated in muscle tissue of a mouse model of CKD. Comprehensive metabolomics revealed that indoxyl sulfate induces metabolic alterations such as upregulation of glycolysis, including pentose phosphate pathway acceleration as antioxidative stress response, via nuclear factor (erythroid-2-related factor)-2. The altered metabolic flow to excess antioxidative response resulted in downregulation of TCA cycle and its effected mitochondrial dysfunction and ATP shortage in muscle cells. In clinical research, a significant inverse association between plasma indoxyl sulfate and skeletal muscle mass in CKD patients was observed. Our results indicate that indoxyl sulfate is a pathogenic factor for sarcopenia in CKD.

    Original languageEnglish
    Article number36618
    JournalScientific reports
    Volume6
    DOIs
    Publication statusPublished - Nov 10 2016

    Fingerprint

    Indican
    Sarcopenia
    Chronic Renal Insufficiency
    Skeletal Muscle
    Pentose Phosphate Pathway
    Metabolomics
    Glycolysis
    Muscle Cells
    Mass Spectrometry
    Up-Regulation
    Down-Regulation
    Adenosine Triphosphate
    Morbidity
    Muscles
    Mortality
    Research

    All Science Journal Classification (ASJC) codes

    • General

    Cite this

    Sato, E., Mori, T., Mishima, E., Suzuki, A., Sugawara, S., Kurasawa, N., ... Ito, S. (2016). Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Scientific reports, 6, [36618]. https://doi.org/10.1038/srep36618

    Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. / Sato, Emiko; Mori, Takefumi; Mishima, Eikan; Suzuki, Arisa; Sugawara, Sanae; Kurasawa, Naho; Saigusa, Daisuke; Miura, Daisuke; Morikawa-Ichinose, Tomomi; Saito, Ritsumi; Oba-Yabana, Ikuko; Oe, Yuji; Kisu, Kiyomi; Naganuma, Eri; Koizumi, Kenji; Mokudai, Takayuki; Niwano, Yoshimi; Kudo, Tai; Suzuki, Chitose; Takahashi, Nobuyuki; Sato, Hiroshi; Abe, Takaaki; Niwa, Toshimitsu; Ito, Sadayoshi.

    In: Scientific reports, Vol. 6, 36618, 10.11.2016.

    Research output: Contribution to journalArticle

    Sato, E, Mori, T, Mishima, E, Suzuki, A, Sugawara, S, Kurasawa, N, Saigusa, D, Miura, D, Morikawa-Ichinose, T, Saito, R, Oba-Yabana, I, Oe, Y, Kisu, K, Naganuma, E, Koizumi, K, Mokudai, T, Niwano, Y, Kudo, T, Suzuki, C, Takahashi, N, Sato, H, Abe, T, Niwa, T & Ito, S 2016, 'Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease', Scientific reports, vol. 6, 36618. https://doi.org/10.1038/srep36618
    Sato, Emiko ; Mori, Takefumi ; Mishima, Eikan ; Suzuki, Arisa ; Sugawara, Sanae ; Kurasawa, Naho ; Saigusa, Daisuke ; Miura, Daisuke ; Morikawa-Ichinose, Tomomi ; Saito, Ritsumi ; Oba-Yabana, Ikuko ; Oe, Yuji ; Kisu, Kiyomi ; Naganuma, Eri ; Koizumi, Kenji ; Mokudai, Takayuki ; Niwano, Yoshimi ; Kudo, Tai ; Suzuki, Chitose ; Takahashi, Nobuyuki ; Sato, Hiroshi ; Abe, Takaaki ; Niwa, Toshimitsu ; Ito, Sadayoshi. / Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. In: Scientific reports. 2016 ; Vol. 6.
    @article{6230d4bb59b34e3286457c5d72ab8525,
    title = "Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease",
    abstract = "Sarcopenia is associated with increased morbidity and mortality in chronic kidney disease (CKD). Pathogenic mechanism of skeletal muscle loss in CKD, which is defined as uremic sarcopenia, remains unclear. We found that causative pathological mechanism of uremic sarcopenia is metabolic alterations by uremic toxin indoxyl sulfate. Imaging mass spectrometry revealed indoxyl sulfate accumulated in muscle tissue of a mouse model of CKD. Comprehensive metabolomics revealed that indoxyl sulfate induces metabolic alterations such as upregulation of glycolysis, including pentose phosphate pathway acceleration as antioxidative stress response, via nuclear factor (erythroid-2-related factor)-2. The altered metabolic flow to excess antioxidative response resulted in downregulation of TCA cycle and its effected mitochondrial dysfunction and ATP shortage in muscle cells. In clinical research, a significant inverse association between plasma indoxyl sulfate and skeletal muscle mass in CKD patients was observed. Our results indicate that indoxyl sulfate is a pathogenic factor for sarcopenia in CKD.",
    author = "Emiko Sato and Takefumi Mori and Eikan Mishima and Arisa Suzuki and Sanae Sugawara and Naho Kurasawa and Daisuke Saigusa and Daisuke Miura and Tomomi Morikawa-Ichinose and Ritsumi Saito and Ikuko Oba-Yabana and Yuji Oe and Kiyomi Kisu and Eri Naganuma and Kenji Koizumi and Takayuki Mokudai and Yoshimi Niwano and Tai Kudo and Chitose Suzuki and Nobuyuki Takahashi and Hiroshi Sato and Takaaki Abe and Toshimitsu Niwa and Sadayoshi Ito",
    year = "2016",
    month = "11",
    day = "10",
    doi = "10.1038/srep36618",
    language = "English",
    volume = "6",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease

    AU - Sato, Emiko

    AU - Mori, Takefumi

    AU - Mishima, Eikan

    AU - Suzuki, Arisa

    AU - Sugawara, Sanae

    AU - Kurasawa, Naho

    AU - Saigusa, Daisuke

    AU - Miura, Daisuke

    AU - Morikawa-Ichinose, Tomomi

    AU - Saito, Ritsumi

    AU - Oba-Yabana, Ikuko

    AU - Oe, Yuji

    AU - Kisu, Kiyomi

    AU - Naganuma, Eri

    AU - Koizumi, Kenji

    AU - Mokudai, Takayuki

    AU - Niwano, Yoshimi

    AU - Kudo, Tai

    AU - Suzuki, Chitose

    AU - Takahashi, Nobuyuki

    AU - Sato, Hiroshi

    AU - Abe, Takaaki

    AU - Niwa, Toshimitsu

    AU - Ito, Sadayoshi

    PY - 2016/11/10

    Y1 - 2016/11/10

    N2 - Sarcopenia is associated with increased morbidity and mortality in chronic kidney disease (CKD). Pathogenic mechanism of skeletal muscle loss in CKD, which is defined as uremic sarcopenia, remains unclear. We found that causative pathological mechanism of uremic sarcopenia is metabolic alterations by uremic toxin indoxyl sulfate. Imaging mass spectrometry revealed indoxyl sulfate accumulated in muscle tissue of a mouse model of CKD. Comprehensive metabolomics revealed that indoxyl sulfate induces metabolic alterations such as upregulation of glycolysis, including pentose phosphate pathway acceleration as antioxidative stress response, via nuclear factor (erythroid-2-related factor)-2. The altered metabolic flow to excess antioxidative response resulted in downregulation of TCA cycle and its effected mitochondrial dysfunction and ATP shortage in muscle cells. In clinical research, a significant inverse association between plasma indoxyl sulfate and skeletal muscle mass in CKD patients was observed. Our results indicate that indoxyl sulfate is a pathogenic factor for sarcopenia in CKD.

    AB - Sarcopenia is associated with increased morbidity and mortality in chronic kidney disease (CKD). Pathogenic mechanism of skeletal muscle loss in CKD, which is defined as uremic sarcopenia, remains unclear. We found that causative pathological mechanism of uremic sarcopenia is metabolic alterations by uremic toxin indoxyl sulfate. Imaging mass spectrometry revealed indoxyl sulfate accumulated in muscle tissue of a mouse model of CKD. Comprehensive metabolomics revealed that indoxyl sulfate induces metabolic alterations such as upregulation of glycolysis, including pentose phosphate pathway acceleration as antioxidative stress response, via nuclear factor (erythroid-2-related factor)-2. The altered metabolic flow to excess antioxidative response resulted in downregulation of TCA cycle and its effected mitochondrial dysfunction and ATP shortage in muscle cells. In clinical research, a significant inverse association between plasma indoxyl sulfate and skeletal muscle mass in CKD patients was observed. Our results indicate that indoxyl sulfate is a pathogenic factor for sarcopenia in CKD.

    UR - http://www.scopus.com/inward/record.url?scp=84994896470&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84994896470&partnerID=8YFLogxK

    U2 - 10.1038/srep36618

    DO - 10.1038/srep36618

    M3 - Article

    AN - SCOPUS:84994896470

    VL - 6

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    M1 - 36618

    ER -